CA
Cabaletta Bio, Inc.
CABA · NASDAQ
$2.46 -6.82% (-$0.18)
1M -20.65%
Market Cap $401.1M
P/E Ratio -
Div. Yield -
ROE 128.27%
Bulios Fair Price
$2
18.7% downside
Current Price
$2.46
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CABA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
90 /100
Cheap P/B 1.90x
P/E N/A
EV/EBITDA N/A
Growth
37 /100
Stable Book val. growth 2.35%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 78.51%
ROE 128.27%
ROA 70.63%
Debt
69 /100
Low Debt/Equity 0.12x
Current ratio 5.79x
Int. coverage -78.11x
Stability
25 /100
Unstable Beta 3.26x
EPS volatility 36.87%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CABA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Steven A. Nichtberger
Employees
156
Headquarters
Philadelphia
Upcoming events
09 NOV
Earnings
Upcoming earnings report